For research use only. Not for therapeutic Use.
CL 218872（Cat No.:I010452）is a selective, non-peptide, and potent antagonist of the vasopressin V1A receptor. It has been studied primarily for its potential therapeutic applications in managing cardiovascular and renal disorders. By blocking the V1A receptor, CL 218872 may help reduce vasoconstriction and fluid retention, making it a candidate for treating conditions such as hypertension, heart failure, and edema. Research is also exploring its effects on regulating blood pressure and its role in modulating the sympathetic nervous system. Ongoing studies aim to further evaluate its safety, efficacy, and clinical potential in various diseases.
| Catalog Number | I010452 |
| CAS Number | 66548-69-4 |
| Synonyms | 3-Methyl-6-[-3-(trifluoromethyl)phenyl]-1,2,4-triazolo[4,3-b]pyridazine |
| Molecular Formula | C13H9F3N4 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | Soluble to 50 mM in DMSO and to 25 mM in ethanol |
| Storage | Store at RT |
| IUPAC Name | 3-methyl-6-[3-(trifluoromethyl)phenyl]-[1,2,4]triazolo[4,3-b]pyridazine |
| InChI | InChI=1S/C13H9F3N4/c1-8-17-18-12-6-5-11(19-20(8)12)9-3-2-4-10(7-9)13(14,15)16/h2-7H,1H3 |
| InChIKey | GUOQUXNJZHGPQF-UHFFFAOYSA-N |
| SMILES | CC1=NN=C2N1N=C(C=C2)C3=CC(=CC=C3)C(F)(F)F |
